Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer.

Ishikawa T, Kokura S, Sakamoto N, Ando T, Imamoto E, Hattori T, Oyamada H, Yoshinami N, Sakamoto M, Kitagawa K, Okumura Y, Yoshida N, Kamada K, Katada K, Uchiyama K, Handa O, Takagi T, Yasuda H, Sakagami J, Konishi H, Yagi N, Naito Y, Yoshikawa T.

Int J Hyperthermia. 2012;28(7):597-604. doi: 10.3109/02656736.2012.695428. Epub 2012 Jul 27.

PMID:
22838644
2.

Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.

Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H; JCOG Gastrointestinal Oncology Study Group.

Jpn J Clin Oncol. 2010 Jun;40(6):573-9. doi: 10.1093/jjco/hyq011. Epub 2010 Feb 25.

PMID:
20185458
3.

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.

Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1426-32. doi: 10.1016/j.ijrobp.2009.06.053. Epub 2010 Jan 7.

PMID:
20056351
4.

Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.

Furuse J, Ishii H, Okusaka T, Nagase M, Nakachi K, Ueno H, Ikeda M, Morizane C, Yoshino M.

Jpn J Clin Oncol. 2005 Dec;35(12):733-8. Epub 2005 Nov 22.

PMID:
16303793
5.

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.

Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E.

Cancer Chemother Pharmacol. 2010 Jul;66(2):395-403. doi: 10.1007/s00280-010-1299-8. Epub 2010 Apr 4.

PMID:
20364428
6.

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):809-16. Epub 2007 Mar 23.

PMID:
17363191
7.

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.

Scheithauer W, Kornek GV, Raderer M, Hejna M, Valencak J, Miholic J, Kovats E, Lang F, Funovics J, Bareck E, Depisch D.

Br J Cancer. 1999 Aug;80(11):1797-802.

8.

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.

Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A.

Cancer Chemother Pharmacol. 2007 Jul;60(2):295-303. Epub 2006 Dec 6.

PMID:
17149608
9.

Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer.

Huang PI, Chao Y, Li CP, Lee RC, Chi KH, Shiau CY, Wang LW, Yen SH.

Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):159-65. doi: 10.1016/j.ijrobp.2008.04.012. Epub 2008 May 26.

PMID:
18508203
10.

A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.

Tomao S, Romiti A, Massidda B, Ionta MT, Farris A, Zullo A, Brescia A, Santuari L, Frati L.

Anticancer Res. 2002 Jul-Aug;22(4):2361-4.

PMID:
12174927
11.

Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.

Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, Pond GR, Hedley D, Wong S, Townsley C, Brezden-Masley C, Moore M.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1027-36. Epub 2006 Dec 29.

PMID:
17197132
12.

Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer.

Zhao H, Yang G, Wang D, Yu X, Zhang Y, Zhu J, Ji Y, Zhong B, Zhao W, Yang Z, Aziz F.

Anticancer Drugs. 2010 Apr;21(4):447-52. doi: 10.1097/CAD.0b013e32833641a7.

PMID:
20075714
13.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM.

J Clin Oncol. 2006 Sep 20;24(27):4441-7.

PMID:
16983112
14.

Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer.

Shibuya K, Oya N, Fujii T, Doi R, Nakamura A, Matsuo Y, Mitsumori M, Hiraoka M.

Am J Clin Oncol. 2011 Apr;34(2):115-9. doi: 10.1097/COC.0b013e3181c4c7a8.

PMID:
20065850
15.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD.

J Clin Oncol. 2005 May 20;23(15):3509-16.

PMID:
15908661
16.

Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.

de Lange SM, van Groeningen CJ, Meijer OW, Cuesta MA, Langendijk JA, van Riel JM, Pinedo HM, Peters GJ, Meijer S, Slotman BJ, Giaccone G.

Eur J Cancer. 2002 Jun;38(9):1212-7.

PMID:
12044508
17.

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF.

Cancer. 2001 Aug 1;92(3):569-77.

PMID:
11505401
18.

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.

J Clin Oncol. 2006 Jan 20;24(3):379-85. Epub 2005 Dec 12.

PMID:
16344320
19.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.

Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.

Oncology. 2004;66(1):32-7.

PMID:
15031596
20.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047

Supplemental Content

Support Center